Pembrolizumab
Merck
['keynote,91', 'key,note,091']
sub group analysis of keynote 091. how to account for favorable dfs in those with egfr mutated pts ? #asco23 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists